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Hepatitis C virus (HCV) is one of the major causes of liver diseases worldwide.  
The non-structural protein 3 (NS3) of HCV, which is both a protease as well as a 
helicase, plays important roles in the processing of the viral polyprotein and the 
replication of viral RNA.  This thesis attempts to answer several questions with regards 
to viral and host interacting proteins of NS3, which may eventually assist in the 
understanding of the mechanism of HCV replication and pathogenesis.  Yeast two-
hybrid assays and co-immunoprecipitation experiments were employed to identify and 
verify these interactions.  The characterization and functional analysis of NS3 
interacting partners are discussed essentially in two parts.  The first part focuses on 
NS3 NS3 self association while the second part describes in detail the interaction 
between NS3 and a cellular protein, LMP7.        
NS3 was found to bind strongly with itself and the minimal region required for 
this interaction was mapped to a specific subdomain of 174 amino acids in the N 
terminus of the helicase region.  Random mutations in this minimal region were 
generated by PCR, and mutants that failed to interact with a wild-type minimal 
fragment were isolated using yeast two-hybrid assay as a screen.  Three of these 
mutations resulted in a reduction or a loss of interaction between helicases.  Analytical 
gel filtration showed that in the presence of an oligonucleotide, wild-type helicases 
form dimers whereas the mutants remain mostly monomeric.  All three mutants were 
partially or almost inactive when assayed for helicase activity in vitro.  Mixing a 
dimerization mutant (Y267S) with wild-type helicase did not dramatically affect 
helicase activity.  These data indicate that dimerization of the helicase is important for 
XII
helicase activity.  The mutations that reduce self-association of the helicase may define 
the key residues involved in NS3-NS3 dimerization (Khu et al., 2001).
Low molecular weight protein 7 (LMP7), an interferon-gamma (IFN-) 
inducible component of the proteasome isolated from a spleen cDNA library was also 
found to bind NS3.  The minimal domain of interaction was defined to be between the 
prosequence region of LMP7 (a.a. 1-40), and the protease domain of NS3.  
Recombinant LMP7 did not have any effect on NS3 protease activity in vitro.  The 
peptidase activities of the LMP7-immunoproteasomes, however, were markedly 
reduced when tested in stable cell line containing a HCV subgenomic replicon 
(Lohmann et al., 1999).  The down regulation of viral antigens for presentation by 
major histocompatibility complex (MHC) class I molecules may thus protect HCV 
from host immune surveillance mechanisms to allow persistent infection by the virus.   
11 Introduction
1.1 Medical Importance of HCV
In the past decades Hepatitis C has risen from obscurity as a disease to being 
recognized today as a major heath problem worldwide.  Hepatitis C was first 
recognized by Prince and colleagues in 1974 as a distinct form of post-transfusion liver 
disease caused by neither hepatitis A nor B virus (Prince et al., 1974).  The search for 
the etiological agent ended with the cloning of parts of the hepatitis C virus (HCV) in 
1989 by Choo and coworkers through the use of random polymerase chain reaction 
(PCR) assays in plasma of chimpanzees chronically infected with non-A non-B 
hepatitis (Choo et al., 1989).  Subsequently, a first generation HCV antibody 
diagnostic kit was developed (Kuo et al., 1989) which helped in the screening of blood 
products and serves as an important clinical diagnostic tool.
HCV infection is identified by World Health Organization (WHO) as one of 
the leading public health problems with approximately 2.2 % of the world’s population 
infected with the virus, which is nearly five times more than human immunodeficiency 
virus (HIV) infected individuals (Tan et al., 2002, WHO 2004).  HCV is primarily 
transmitted through contaminated blood, blood products, and less effectively through 
human body secretions such as saliva, and semen (Zanetti et al., 2003).  Blood 
transfusion was the most common mode of transmission in the early 1990s before 
blood products were screened for HCV (Miyamura et al., 1990), more recently, 
however, intravenous drug abuse has been the main route of transmission (Memon and 
Memon, 2002).   
2The hallmark of HCV infection is the high frequency of viral persistence in the 
host, and as much as 80 % of chronic HCV infections lead to chronic hepatitis.  Most 
infections are not diagnosed, as many patients can remain asymptomatic for decades.  
As the disease progresses, a spectrum of liver conditions such as steatosis, cirrhosis 
and hepatocellular carcinomas develop.  Hepatitis C is the major indicator for liver 
transplantation, making this pathogen a serious medical and socioeconomic problem 
(WHO, 1998).  At the moment, there is no protective vaccine against HCV and 
therapeutic options are still limited.  For more than a decade, interferon (IFN)- was 
used in the treatment of hepatitis C infection but the results have been disappointing as 
most patients were unable to have sustained virologic response (Neumann et al., 1998).  
Although recent therapies based on a combination of polyethylene glycol (PEG) 
conjugated IFN- and ribavirin, a synthetic guanosine analogue, were able to achieve 
significant improvement in sustained response rates, HCV viremia is still not 
eradicated in more than 50 % of patients treated and is accompanied by severe side 
effects (Liang, 1998; Di Bisceglie and Hoofnagle, 2002).  
Based on sequence analogy, HCV is divided into six major genotypes with more 
than 20 subtypes and numerous quasispecies (Miyakawa et al., 1995; Simmonds et al., 
1999).  The genotypes vary in their geographical distributions, response to therapy and 
severity of the disease they cause.  Subtypes 1a and 1b are common in United States 
and Europe, while subtype 1b is most common in Asian countries (Dusheiko et al., 
1994; McOmish et al., 1994).  Interestingly, patients infected with genotype 1b 
respond poorly to IFN- therapy as compared to those infected with genotypes 2 and 3 
(Zein, 2000).  The mechanism utilized by HCV to counteract IFN is still poorly 
understood.  Much work is needed in the formulation of new HCV therapies.  
Unfortunately, the development of antiviral drugs has been hindered by the existence 
3of HCV quasispecies, the absence of small animal models and reliable cell culture 
systems for robust propagation of the virus (Wyatt et al., 1998; Lohmann et al., 1999).      
1.2 Molecular biology of HCV
HCV is a member of the family Flaviviridae classified under a separate genus 
Hepacivirus.  Other genera of this family include the Flaviviruses e.g. yellow fever 
virus, Japanese encephalitis virus, and dengue virus, and the Pestiviruses e.g. classical 
swine fever virus and bovine viral diarrhea virus (Robertson et al., 1998).  Viruses of 
the family Flaviviridae have in common a single sense strand RNA genome carrying a 
long open reading frame (ORF) flanked at the 5’ and 3’ ends by untranslated regions 
(UTR).  The HCV genome is approximately 9600 nucleotides in length and encodes a 
single polyprotein of about 3010 to 3033 amino acids (aa) depending on the genotype 
(Miller and Purcell, 1990; Choo et al., 1991).  A schematic depiction of the HCV 
genome is shown in Figure 1-1.  The 5’ UTR of HCV is typically 341 bases long and is 
the most conserved portion of the HCV genome.  This region is characterized by multi 
stem-loop structures, which contribute to an internal ribosomal entry site (IRES), 
mediating cap-independent translation of viral RNA (Friebe et al., 2001).  The 3’ UTR 
of 200 to 300 nt contains a short variable sequence of approximately 40 nt followed by 
a poly(U-U/C) region of variable length and a highly conserved 98 nt region 
implicated to be important for minus strand synthesis (Friebe et al., 2002).
41.2.1 Structural Proteins
The HCV polyprotein is cleaved co- and post-translationally at several sites by 
both viral encoded and host cellular proteases into mature viral proteins.  About 10 
distinct viral proteins have been identified which include at least three structural, Core, 
E1 and E2 (and p7), six non-structural (NS) proteins, NS2, NS3, NS4A NS4B, NS5A 
and NS5B (Hijikata et al., 1991) (see Figure 1-1).  Cleavage of the structural proteins 
by host signal peptidase in the lumen of the endoplasmic reticulum (ER) first releases 
the core protein, followed by envelope proteins E1 and E2.  These structural proteins 
have in common hydrophobic domains in their C termini which are important for 
membrane association and subsequent cleavage by the signal peptidases.  The core 
protein is strongly basic in nature and interacts with viral RNA to form the 
nucleocapsid (Hussy et al., 1996a).  This highly conserved protein is very 
immunogenic and is used frequently for antibody detection in patient sera (Hosein et 
al., 1991).  Glycoproteins E1 and E2 are the viral envelope proteins (Hussy, 1996b).  
These two proteins form heterodimers and dimerization is suggested to be important 
for their correct folding during viral assembly (Michalak et al., 1997).  The E2 protein 
contains sequences at the N terminus that are the most variable within the HCV 
genome, named hypervariable region (HVR) 1 and 2.  The HVR regions seem to be the 
only target for neutralizing antibodies (Weiner et al., 1992).  The function of the small 
p7 protein at the moment is still unclear but was recently shown to contain important 
genotype specific sequences and is essential for the infectivity of HCV (Griffin et al., 
2003; Sakai et al., 2003).   




















































































































































































































































































































The NS proteins of HCV encode enzymes or regulatory factors that are 
believed to catalyze and regulate the replication of the HCV RNA genome.  The NS 
polypeptide is processed by two viral proteases.  The first protease, NS2/3, which 
spans the C terminus of NS2 and N-terminus of NS3, is a zinc-dependent 
metalloprotease that undergoes autocatalysis to generate NS2 and NS3 (Grakoui et al., 
1993).  Once cleaved from NS3, NS2 is not essential for the HCV replication when 
tested in subgenomic replicons (Lohmann et al., 1999; Blight et al., 2000).
The second protease activity of HCV is found in NS3, a multi-catalytic protein.  
The N terminus one third of NS3 encodes a serine protease with three highly 
conserved amino acid residues His-53, Asp-77, and Ser-138, which are catalytic triads 
of the serine protease family (Miller et al., 1990).  This protease cleaves at the 
NS3/NS4A, NS4A/4B, NS4B/5A, and NS5A/5B junctions, releasing the mature NS3, 
NS4A, NS4B, NS5A and NS5B.  The cleavage between NS3/4A occurs in cis as a 
spontaneous rapid autocatalytic event, while cleavage at the other sites can occur in 
trans when exogenous NS3 is added (Bartenschlager et al., 1993; Tomei et al., 1993).  
NS4A is a cofactor for NS3 protease activity, it is vital for cleavages at the NS3/4A 
and NS4B/5A sites, and enhances processing of the NS4A/4B and NS5A/5B sites 
(Tanji et al., 1995).  The binding of NS4A to NS3 also helps anchor the NS3-NS4A 
complex onto the ER where proteolytic processing takes place (Lin and Rice, 1995).  
The remainder two thirds of NS3 encodes the viral nucleoside triphosphatase 
(NTPase) and helicase.  Viral helicase is thought to participate in viral replication and 
transcription by unwinding the extensive RNA secondary structures in the HCV 
genome for the synthesis of the complementary strand and the translation of viral 
products.  The intrinsic NTPase activity of the helicase provides the energy source for 
7unwinding by hydrolyzing nucleoside triphosphate (Suzich et al., 1993; Kim et al., 
1995).  As revealed by sequence analysis and crystal structures of NS3 helicase, this 
protein belongs to the DEXH box RNA helicase family with conserved sequences 
G207SGKST, D290ECH, T322AT, and Q460RRGRTGRGRGG (Gorbalenya et al., 1988; 
Cho et al., 1998).  The G207SGKST sequence, also known as the Walker A sequence, 
is found in most NTP hydrolyzing enzymes and is needed for binding NTP.  Walker B 
sequence D290ECH is involved in NTP hydrolysis (Walker et al., 1982).  The T322AT 
motif is important for unwinding RNA while the Q460RRGRTGRGRGG motif is 
responsible for binding RNA (Pause and Sonenberg, 1992; Gross and Shuman, 1996).  
The NS3 helicase can unwind double stranded (ds) RNA as well as dsDNA and RNA-
DNA heteroduplexes in a 3’ to 5’ direction.  This activity also requires the presence of 
divalent ions such as Mg2+ or Mn2+ and ATP (Tai et al., 1996; Wardell et al., 1999).  
The NS3 protease activity is enhanced by NS4A (Bartenschlager et al., 1994; Failla et 
al., 1994).  NS4A was also shown to affect helicase activity (Gallinari et al., 1999; 
Pang et al., 2002).  The function of NS4B is poorly understood but is most likely to be 
an integral part of the viral replication complex.  
The role of NS5A, a highly phosphorylated protein, in HCV replication is 
unclear.  Sequence comparison of IFN- sensitive and IFN- resistant HCV isolates, 
however, reveals a cluster of amino acid differences, termed interferon sensitivity 
determining region (ISDR), which correlates with IFN response (Enomoto et al., 
1996).  NS5B is the viral RNA dependent RNA polymerase (RdRp) with a GDD 
motif, which is a hallmark of RNA polymerase of RNA viruses (Poch et al., 1989).  
NS5B is the key enzyme involved in the generation of the complementary minus 
strand RNA using the viral genome as template and the subsequent synthesis of the 
progeny genomic plus strand RNA (Behrens et al., 1996).  Similar to NS3, NS5B 
8activity is also dependent on the presence of divalent ions (Lohmann et al., 1998).  The 
high replication rate and low fidelity activity of NS5B were also associated with the 
emergence of HCV quasispecies, a major obstacle to anti-viral therapy development 
(Smith et al., 1997).
Although there has been much progress in the molecular biology of HCV, 
studies on this virus are greatly impeded by the lack of small animal models and a 
robust in vitro infectious cell culture system.  Humans are the only known natural host 
for HCV.  There is no evidence for vector-mediated transmission.  By far the 
chimpanzees are the most reliable animal models for studying HCV infection.  
Consequently, the mechanism of HCV replication is based primarily on experiences 
drawn from closely related flavi- and pestiviruses.  Recent years, however, have seen 
some advancement in the HCV arena.  Several groups have reported the use of the 
Tupaia belangeri, a closely related primate of the chimpanzee (Xie et al., 1998; Zhao et 
al., 2002), and chimeric mouse models, in which human hepatocytes are transplanted 
on immunocompromised mice, as potential models for studying HCV infection 
(Mercer et al., 2001).  The generation of HCV-replicon systems, where the expression 
of the HCV NS proteins drives the self-replication of subgenomic HCV RNAs 
(Lohamnn et al., 1999; Blight et al., 2000), will also undoubtedly help accelerate our 
understanding of HCV replication and propagation.
91.3 HCV protein-protein interaction
Viral proteins are known to interact with one another in the formation of the 
viral replication complex.  The HCV replicase complex is believed to be ER 
membrane associated, comprising of at least NS3 and NS5B as well as several host 
cofactors, similar to several plus strand RNA viruses, such as poliovirus and 
flaviviruses (Bolten et al., 1998; Westaway et al., 1997).  The HCV NS5B was 
reported to complex with NS3 and NS4A (Ishido et al., 1998), reminiscent of the 
association between NS5 and NS3 of dengue virus type 2 and Japanese encephalitis 
virus (Kapoor et al., 1995; Chen et al., 1997).  NS4A, NS4B and NS5A have also been 
found to form a complex (Lin et al., 1997), so do NS5A and NS5B (Shirota et al., 
2002).  All the HCV NS proteins interact with each other either directly or indirectly, 
supporting the hypothesis of functional multi-subunit replicase complex.  
Viruses are dependent on protein synthesis machineries in the host for viral 
protein translation, and other cellular components for their replication.  HCV proteins 
were reported to associate with several host proteins.  E2 binds the putative cellular 
receptors, CD81 and the low-density lipoprotein receptor (LDLR) (Pileri et al., 1998; 
Agnello et al., 1999; Wunschmann et al., 2000), which may act as receptors for HCV 
entry into target cells.  A cellular chaperon, HSP90, was reported to bind NS2/3 and is 
needed for successful cleavage at the NS2/3 site by helping in the proper folding of 
newly synthesized NS2/3 (Waxman et al., 2001).  A human eukaryotic initiation factor 
4AII with RNA dependent ATPase/helicase activity was found to bind NS5B and 
facilitates viral translation by unwinding the secondary structures of the 5’ UTR 
(Kyono et al., 2002).  p68, a cellular helicase, was also reported to assist in HCV 
replication by binding to NS5B (Goh et al., 2004).    
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The direct pathogenic effect of HCV replication, however, is not clear but 
studies on transgenic mice models expressing either the structural proteins alone or 
both structural and nonstructural proteins presented similar phenotypes, including 
steatosis, oxidative stress, and hepatic tumors.  The interaction between core and lipid 
vesicles was implicated in HCV-related steatosis reflecting abnormal lipid metabolism 
(Moriya et al., 1997).  The core protein alone was also shown to be capable of causing 
oxidative stress as well as tumor formation (Moriya et al., 1998; Okuda et al., 2002) 
but another group showed that the full-length HCV polyprotein is needed to induce 
tumors (Lerat et al., 2002).  As to how, the virus can remain undetected by the host 
immune system for decades remain controversial.   One of the strategies suggested was 
the binding of NS5A to double-stranded RNA-dependent protein kinase (PKR) at its 
ISDR motif thereby avoiding the anti-viral effect of IFN (Gale et al., 1997).  Besides 
NS5A, E2 glycoprotein was also reported to bind and inhibit the activity of PKR 
(Taylor et al., 1999).  
Alignments of amino acid sequences have revealed that the serine protease and 
NTPase/helicase motifs of NS3 are highly conserved in the Flaviviridae family and 
among different HCV genotypes (Miller and Purcell, 1990).  Productive replication 
was also abrogated in vivo when NS3 is mutated at the active sites, making this protein 
an attractive target for drug discovery (Kolykhalov et al., 2000).  Besides the obvious 
role of NS3 in viral replication, this protein may also play a role in regulating cell 
proliferation through its interaction with p53 tumor suppressor (Ishido and Hotta, 
1998).  NS3 was also reported to transform NIH 3T3 cells (Sakamuro et al., 1995) as 
well as rat 3T3 cells (Zemel et al., 2001), implicating its involvement in oncogenesis.  
Taken together, most of the viral proteins interact and may affect the activities of host 
proteins in the long-term.  The understanding of the interplay between viral and host 
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proteins will shed light on the mechanism involved in HCV pathogenesis and help in 
the formulation of more efficient treatments for HCV. 
1.4 Aims and Objectives
The mechanisms by which HCV replicates and the tactics employed by the 
pathogen to remain undetected for years are ill defined.  Studies on the functions of 
viral - viral as well as viral - host interactions will provide valuable information on 
understanding these mechanisms of evasion from host immune surveillance, and will 
be useful for the development of anti-HCV therapies.  This thesis aims to identify both 
viral and host interacting partners to NS3, a pivotal player in HCV replication, in the 
hope of providing new insights into understanding function and effect of these 
interactions.  Yeast-two hybrid screens were set up to identify HCV proteins as well as 
host proteins that interact with NS3, using a spleen cDNA library.  The functions of 
these interactions were investigated and discussed in two parts.  The first section 
describes the characterization of NS3 self-interaction, while the second part covers the 
interaction between NS3 and host proteins, in particular, between NS3 and LMP7.    
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2. Materials and Methods
2.1 Construction of Plasmids
The NS3 coding sequence was amplified from HCV RNA extracted from 
HCV-positive serum (Lim et al., 2001) by RT-PCR.  For the yeast two-hybrid screen, 
NS3 clones were fused in frame with the Gal4 DNA binding domain in pAS2-1 vector 
and Gal4 DNA activating domain in pACT2 (Clontech).  For mammalian expression 
of flag- or myc-tagged proteins, DNA fragments were cloned into pXJ40-flag, pXJ40-
myc or pXJ100-myc (Manser et al., 1997) respectively.  For expression of glutathione 
S-transferase (GST) tagged proteins in bacteria, constructs were made in pGEX-2TK 
vector (Pharmacia).  LMP7 coding region was amplified by PCR from the spleen 
cDNA library with primers OLG144 
(CGCGGATCCATGGCGCTACTAGATGTATGC) which contained a BamHI site, 
and OLG 145 (CCGCTCGAGTTATTGATTGGCTTCCCGGTA) which contained a 
XhoI site.  Vectors, plasmids used in studying NS3-NS3 interaction and NS3-LMP7 
interaction are summarized in Tables 2-1, 2-2 and 2-3 respectively.
2.2 Yeast two-hybrid screens
2.2.1 NS3 NS3 interaction
Yeast two hybrid screens were performed as described in the Matchmaker 
user’s manual (Clontech).  Interaction between NS3 fragments were indicated by the 
activation of the reporter genes HIS3 and ADE2, which would allow yeast cells to 
grow on –His and –Ade media respectively, and LacZ, a -galactosidase (-Gal) that 
produce a blue colour when the substrate X-Gal (5-bromo-4-chloro-3-indolyl--D-
13
galactopyranoside) (Sigma) is cleaved.  Ade+ and LacZ+ phenotypes represented 
stronger interactions compared to His+ phenotype.  The pAS2-1 and pACT2 constructs 
were transformed into PJ69-2A (MATa trp1-901 leu2-3,112 ura3-52 his3-200 ade2-
101 gal4 gal80 LYS2::GALUAS-GAL1TATA-HIS3 GAL2UAS-GAL2TATA-ADE2) and 
Y187 (MAT trp1-901 leu2-3,112 ura3-52 his3-200 ade2-101 gal4 gal80 met-
URA3::GALUAS-GAL1TATA-LACZ), respectively.  To test for interaction, the two strains 
carrying various fragments of NS3 were mated on yeast extract-peptone-dextrose 
(YEPD) plates and then transferred onto -Trp -Leu plates to select for diploids that 
have both plasmids.  They were then replica plated onto -Trp -Leu -His and -Trp -Leu -
Ade plates and also assayed for -Gal activity.  Interactions were confirmed by 
retransforming the pairs of constructs into the haploid strains PJ69-2A and Y187 and 
assaying for the activation of the appropriate reporter genes.  The -Gal activity assay 
is done by lifting patches of cells from a plate onto a nylon membrane (Hybond N; 
Amersham), placing the membrane, with the cells facing up, on a fresh plate to allow
the patches of cells to grow for a day, and then performing a "blue" assay on the 
membrane.  The membrane was dipped in liquid nitrogen for a few seconds and then 
transferred (cells facing up) onto a piece of filter paper (3M) soaked in 1.8 ml of Z 
buffer (60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4) and 25 µl of 
X-Gal (25 mg/ml dissolved in dimethylformamide).  Membranes were incubated at 
30°C to allow the blue colour to develop (up to a few hours).
2.2.2 NS3 Host interaction
Yeast two-hybrid screens of a human spleen cDNA library transformed onto 
PJ69-2A carrying pAS-NS3 also performed according to the Matchmaker user’s 
manual (Clontech). Interaction between NS3 and host proteins in pACT2 from the 
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library was indicated by the activation of the reporter genes HIS3 and ADE2, which 
would allow yeast cells to grow on –His and –Ade media respectively.  Plasmids from 
positive library clones were sequenced and re-cloned into XJ100-myc vector for 
verification by in vitro binding and co-IP assays.
2.3 Generation of mutations in NS3 helicase
A two-step PCR was used to generate site-directed mutations. 
Random mutations in the minimal region were generated by lowering the 
nucleotide ratio of each of the four nucleotides to 1:4:4:4 (final concentrations are 
25 µM:100 µM) in four separate PCRs using BD forward 
(TCATCGGAAGAGAGTAGT) and BD reverse (CGTTTTAAAACCTAAGAGTCA) 
primers on template pFG150 (pAS-min) (See Fig. 2-1).  The products of the four 
reactions were pooled, and the resulting product was cotransformed with a gapped 
plasmid containing a deletion in the minimal region into PJ69-2A (pFG166 cut with 
EagI).  Plasmids become repaired in yeast to generate a circular plasmid (Mulrad et al., 
1992).  This pool of transformed cells was mated overnight with a Y187 strain 
containing pACT-min in YEPD liquid medium.  An aliquot of mated cells was plated 
on -Trp -Leu medium, while the rest were kept at 4°C.  This gives an estimate of the 
amount of cells to be plated to give an appropriate density for screening (about 500 to 
700 per plate).  After about 2 days, the remaining cells were diluted accordingly and 
then plated on -Trp -Leu plates and incubated at 30°C until colonies appeared.  The 
colonies were replica plated onto -His -Trp -Leu plates to identify colonies that could 
not grow on -His medium, indicating a lack of interaction.  Plasmids from these 
mutants were extracted and transformed into bacteria.  To quickly check that they 
contained a properly repaired plasmid, PCR was done directly on the bacterial cells 
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with BD forward and BD reverse primers.  Those that contained an insert were 
amplified and retransformed into PJ69-2A carrying pACT-min and tested for 
interaction on -His -Trp -Leu medium.
Figure 2-1.  Scheme showing the generation of random mutants that disrupt 
helicase interaction.
Random mutants were generated by low-fidelity PCR and recombined with a gapped plasmid in yeasts.  
Transformed yeasts carrying repaired plasmids were mated with a strain carrying the pact-min plasmid, 
and diploids were screened for mutants that did not interact with pACT-min and were therefore His-.   
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2.4 NS3 helicase and helicase mutants expression, purification and 
analytical gel filtration
To express the helicase in bacteria, the helicase region (aa 181 to 630) was 
cloned into a derivative of the bacterial expression vector pGEX-2TK (Pharmacia) and 
transformed into BL21 (Stratagene).  The GST-helicase fusion protein expression was 
induced in the presence of 1 mM isopropyl-1-thio--D-galactopyranoside (IPTG) and 
cultured for 3 h at 37°C.  For the dimerization mutants, protein expression was induced 
at 18°C overnight with 0.5 mM IPTG, and cells were harvested and sonicated once in 
lysis buffer (50 mM Tris-HCl [pH 7.6], 1 mM -mercaptoethanol, 1 mM EDTA, 1% 
Triton X-100, 100 mM NaCl, 5% glycerol) and a second time in 300 mM NaCl in lysis 
buffer both supplemented with 1 mM protease inhibitor phenylmethylsufonyl fluoride 
(PMSF).  These conditions appear to increase the yield and solubility of the mutant 
proteins.  The cells from 1 liter of culture were harvested and disrupted with a 
Microson ultrasonic homogenizer (model XL2000) in 10 pellet volumes of lysis buffer.  
The insoluble materials were pelleted at 18,000 rpm for 45 min in a Sorvall SS34 rotor, 
and 500 µl of glutathione (GSH) Sepharose 4B beads (Pharmacia) was added to the 
clarified supernatant.  The beads were allowed to bind for 2 h, and then they were 
washed four times in lysis buffer and four times in cleavage buffer (50 mM Tris [pH 
8], 150 mM NaCl, 0.1% -mercaptoethanol, 2.5 mM CaCl2, and 1 mM dithiothreitol 
[DTT]).  The helicase was cleaved from the GST moiety with thrombin (10 U/liter of 
culture; Sigma) for 45 min.  All steps were performed at 4°C unless otherwise stated. 
NS3 helicase was then purified by fast-performance liquid chromatography 
(FPLC) using a 24-ml S200 Sepharose column (Pharmacia) in binding buffer [50 mM 
Tris-acetate (pH 7.5), 40 mM sodium acetate (NaOAc), 10 mM Mg(OAc)2, 10% 
glycerol].  NS3 helicase was found to be >95% pure as determined by sodium dodecyl 
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sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with Coomassie blue staining.  
Dimerization was shown by analytical FPLC on a SMART machine (Pharmacia) in
binding buffer in either the absence or presence of a 39-mer oligonucleotide (OLG39: 
3'ATAATGTGTGCTGCCTGCCACTCAACTGACTCAACT5').  A 100-µl volume
containing helicase at 5 µM and oligonucleotide ranging from 0 to 5.0 µM was used 
for each run. 
2.5 Helicase activity assay
A double-stranded oligodeoxynucleotide was used as a substrate for helicase 
activity assays, since NS3 helicase was shown to be about as effective in unwinding 
DNA as RNA duplexes (Tai et al., 1996).  The substrate was made by annealing the 




(Genset Inc.), which when annealed give a 25-bp 3' overhang at both ends.  OLG54 
was end labeled with polynucleotide kinase (New England Biolabs) using [-32P]ATP 
and purified using a nucleotide purification kit (Qiagen).  The two overlapping single-
stranded DNAs were mixed with a molar excess of the unlabeled oligonucleotide and 
annealed by cooling the mixture from 75°C to room temperature gradually.  Each 
reaction contained 20 nM substrate and 400 nM helicase in binding buffer made up to a 
total of 10 µl in helicase reaction buffer (20 mM HEPES-KOH [pH 7.0], 2 mM DTT, 
1.5 mM MnCl2, 2.5 mM ATP, 0.1 mg of bovine serum albumin per ml).  The reactions 
were terminated by adding 5 × DNA gel loading dye, and products were run on 10%
acrylamide gels (29:1, acryl-bis) in 0.5 × Tris-borate-EDTA buffer. The gel was dried, 
18
and radioactivity in the single- and double-stranded DNA and protein-bound DNA was 
detected on an autoradiograph or quantitated on a PhosphorImager (Molecular 
Dynamics).  The percent single-stranded, or unwound, DNA was calculated as the 
percentage of the total radioactivity that was present in the unwound DNA in each 
reaction mixture. 
2.6 In vitro binding assay
Candidate host genes obtained from yeast two-hybrid screens of spleen cDNA 
library were re-cloned into pXJ100-myc for in vitro transcription and translation. The 
proteins were 35S-methionine-labeled using the TNT Quick Coupled transcription 
translation system (Promega) following manufacturer’s instructions.  The in vitro
translated products were then added to 5 µg GST-NS3 or GST bound to GSH beads 
and incubated for 1 h at room temperature with gentle agitation.  The beads were 
washed four times with lysis buffer supplemented with 1 mM PMSF, and the bound 
proteins separated on SDS-PAGE gels.  The gels were dried and bound proteins were 
detected by autoradiography.  
2.7  FL-NS3, LMP7 expression and purification
BL21 bacteria cells (Stratagene) transformed with pGEX-NS3 were induced 
with 1 mM IPTG overnight at 30oC.  Cells from a 1 liter of culture were pelleted and 
re-suspended in 5 ml buffer A (phosphate buffered saline [PBS] containing 1mM DTT, 
and 1% Triton X-100) supplemented with 1 M NaCl and 1 mM PMSF before 
sonication in a Microson ultrasonic homogenizer (model XL2000).  Cell debris were 
spun down at 18,000 rpm for 30 min in a Sorvall SS34 rotor.  The clarified supernatant 
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was then reconstituted to 0.3 M NaCl with buffer A and 500 µl of GSH Sepharose 4B 
beads (Pharmacia) were added.  The GST-NS3 protein was rolled with GSH beads for 
2 h, washed three times with buffer A containing 1 M NaCl and finally another three 
times with GSH wash buffer (50 mM Tri-HCl [pH8.0], 1 mM DTT).  GST-NS3 fusion 
protein was eluted from GSH beads overnight in GSH elution buffer (50 mM Tri-HCl, 
1 mM DTT, 150 mM NaCl, 0.1 % Triton X-100, 10 mM reduced glutathione).  Three 
subsequent washes were collected, concentrated and dialyzed in buffer B (20 mM Tris-
HCl [pH 6.7], 1 mM DTT, 10 % glycerol) in a Biomax Ultra free centrifugal filter 
(molecular weight cut off 50 kDa; Millipore).  To further purify GST-NS3, FPLC 
using a 1 ml HiTrap SP column (Pharmacia) was performed.  The column was pre-
equilibrated in buffer B and the proteins were eluted through a linear gradient of 0 to 1 
M NaCl in buffer B.
Plasmid pGEX-LMP7 was transformed into BL21 for expressing GST-tagged 
LMP7.  Protein expression was carried out using the same procedure as for GST-NS3.  
After binding, GST-LMP7-bound beads were washed three times with buffer A 
containing 1 M NaCl and another three times with thrombin cleavage buffer.  GST was 
cleaved from LMP7 with thrombin (5U/liter culture; Sigma) for 1 h.  LMP7 was 
purified following the same procedure as for GST-NS3.  Purified fractions were stored 
at – 80oC until use.  All experiments were performed at 4oC unless otherwise stated.
Plasmid pGEX-NS5A5B (Sing et al., 2001) was transformed into BL21 for the 
expression of GST-NS5A5B fusion protein for use as an NS3 protease substrate.  
GST-NS5A5B was expressed and purified on GSH-beads in the same manner as for 
GST-NS3.  
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2.8 In vitro protease activity assay
The protease activity of GST-NS3 was determined by the cleavage of GST-
NS5A5B.  To investigate the effect of LMP7 on NS3 protease activity in vitro, 
different amounts of purified LMP7 0.2 µg to 0.6 µg (equivalent to 0.3 µM to 1.0 µM), 
were added to the in vitro cleavage reaction.  Each reaction consisted of 0.2 µg purified 
GST-NS3, varying amounts of LMP7, 2 µg GST-NS5A5B bound to beads and 1 µg 
NS4A peptide (a.a 18 to 40) (Bioprocessing Technology Centre, Singapore) made up 
to a final volume of 20 µl in protease assay buffer (50 mM Tri-HCl [pH 8.0], 30 mM 
NaCl, 5 mM CaCl2, 10 mM DTT).  The reaction mix was incubated at 37oC with gentle 
agitation for 30 min.  Reaction was stopped by adding SDS loading buffer and the 
cleavage of GST-NS5A5B (40 kDa) to a smaller protein of about 30 kDa was observed 
by Coomassie staining on an SDS-PAGE gel.
2.9 Proteasome activity assay
Proteasomes were isolated from HeLa, Huh-7 or stable cell line, 9-13, which 
contains self-replicating HCV subgenomic RNA in Huh-7 cells (Lohmann et al., 1999, 
kindly provided by R. Bartenschlager laboratory).  HeLa or Huh-7 cells on a 10-cm 
plate (Nunc) were transfected with either 1.25 µg pXJflag-NS3 or 0.4 µg pXJflag-GST 
using Lipofectamine (Invitrogen) for 6 h prior to LMP7 induction by the addition of 
100 U/ml interferon-gamma (Roche).  Similarly in 9-13 cells, LMP7 was also induced 
by adding 100 U/ml interferon-gamma.  Huh-7 cells were also induced as controls.  
After 24 h incubation at 37oC, cells were harvested in lysis buffer supplemented with 1 
mM PMSF.  Cell lysate containing 1.0 mg total protein was incubated with 100 µl 
anti-alpha 4 subunit-conjugated agarose (Affiniti) overnight at 4oC.  The beads were 
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then washed three times with lysis buffer followed by another three washes with 
proteasome assay buffer (20 mM Tris-HCl [pH 7.5]) and finally re-suspended in 500 
µl of the same buffer.  
Proteasome assay was optimized using proteasome isolated from either 
pXJflag-NS3- or pXJflag-GST-transfected HeLa or Huh-7 cells.  Each set of assay 
consisted of different amounts of protein containing immunoprecipitated proteasome 
complex (0, 0.3, 0.6, 1.2, 2.5 µg) with either 100 µM or 200 µM substrates in a final 
volume of 150 µl proteasome assay buffer, incubated for 1 h at 37 oC with gentle 
agitation.  Three fluorogenic substrates were tested Suc-Leu-Leu-Val-Tyr-AMC 
(LLVY), Boc-Leu-Arg-Arg-AMC (LRR) (Affiniti), and Z-Leu-Leu-Glu-AMC (LLE) 
(Boston Biochem).  To optimize reaction time, reaction mix containing a fixed amount 
of protein containing immunoprecipitated proteasome (0.6 µg) and 100 µM substrate in 
a final volume of 150 µl assay buffer was incubated with gentle agitation at 37 oC for 
different time intervals (0, 10, 20, 30, 40, 50 min).  After each reaction, the reaction 
mix was spun briefly and 100 µl reaction mix was quenched with 100 µl cold ethanol.  
Fluorescence measurements were read by a spectrofluorometer (Tecan) at 360 nm 
excitation and 465 nm emission on a 96 well black F16 Maxisorp plate (Nunc).  Each 
assay was performed in triplicates.
For proteasome isolated from 9-13 cells, each proteasome assay consisted of 
0.6 µg immunoprecipitated proteasome complex, 0.1 mM LLVY-AMC, LRR-AMC, 
or LLE-AMC, with or without the proteasome inhibitor clasto-lactacystin -lactone 
(Affiniti) in a final volume of 150 µl proteasome assay buffer.  The reaction mix was 
incubated for 20 min at 37oC, after which 100µl reaction mix was quenched with 100 
µl cold ethanol.  Fluorescence measurements were read by a spectrofluorometer at 360 
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nm excitation and 465 nm emission on a 96 well black F16 Maxisorp plate.  Each 
assay was performed in triplicates.
2.10 Immunoprecipitation (IP)
COS-7 cells on 6 cm plates were transfected with 0.5 µg of DNA using 
Effectene (Qiagen) according to the supplier's instructions. Twenty-four hours after 
transfection, cells were washed once in PBS and harvested in lysis buffer with 1mM 
PMSF at 4°C.  Total cell lysate (0.15 mg) was incubated (with rolling) with 20 µl of 
anti-flag agarose gel (Sigma) overnight at 4°C.  The gel was washed five times, each 
time with 1 ml of lysis buffer, and the proteins bound to the gel were extracted by 
boiling for 2 min in 2 × sample buffer and separated by SDS-PAGE. 
2.11 Western blot analysis
To analyze proteins from co-IP experiments and protein expression in 
transfected cells, protein samples were resolved by SDS-PAGE, transblotted onto 
Hybond-C membranes (Amersham), and were probed with anti-myc polyclonal (Santa 
Cruz Biochemicals) at 1:1000 dilution, anti-flag polyclonal (Sigma) at 1:5000 dilution, 
anti-GST polyclonal (Santa Cruz Biochemicals) at 1:10 000 dilution, anti-NS3 
monoclonal (Devaron) at 1:5000 or anti-LMP7 monoclonal (Affiniti) at 1:500 dilution 
overnight at 4°C or at least 1 h at room temperature. After extensive washes, a 
secondary antibody conjugated to horseradish peroxidase (1:2,000 dilution; Pierce) was 
applied to the blots for at least 1 h at room temperature. Washes were done six times 
for 5 min each in 0.05% Tween 20 in PBS. Antibodies were diluted in 3% skimmed 
milk in PBS with 0.05% Tween 20.  Blots were washed, and reagents for enhanced 
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chemiluminescence (Pierce) were added for 5 min before signal was detected on X-ray 
film (Hyperfilm). 
2.12 Tissue culture
COS-7, a monkey kidney fibroblast, and HeLa, a human cervical carcinoma 
cell line, purchased from American Type Cell Culture Collection, were maintained in 
standard DME medium supplemented with 10% fetal calf serum (HyClone 
Laboratories) and antibiotics, penicillin at 10 units/ml and streptomycin at 100 µg/ml 
(Sigma).  9-13 stable cell line was maintained in standard DME medium supplemented 
with 10% fetal calf serum, penicillin at 10 units/ml, streptomycin at 100 µg/ml and 1 
mg/ml Geneticin (GIBCO).   
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aIMCB, Institute of Molecular and Cell Biology, Singapore.
Table 2-1.  Vectors used in this study
Vector Description Source








pXJ40-flag Mammalian expression vector for tagging proteins with 
Flag at the N terminus.
Manser et 
al., 1997
pXJ40-myc Mammalian expression vector for tagging proteins with c-





Mammalian expression vector, modified from pXJ40-myc 
for tagging proteins with c-myc at the N terminus with NotI 
and HincII sites in the same frame as in pACT2.
CAVR lab, 
IMCB
PGEX-2TK GST fusion expression vector with modified multiple 
cloning sites
S. C. Lin 
lab, IMCB
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Table 2-2.  Plasmids used in studying NS3-NS3 interaction
Plasmid Description Source
pFG105 pAS-NS3 (NS3 a.a. 1 - 630) Khu et al., 
2001
pFG106 pACT-NS3 (NS3 a.a. 1 - 630) Khu et al., 
2001
pFG346 pXJflag-GST (flag-GST) Glaxo lab, 
IMCB
pFG109 pXJflag-NS3 (flag-NS3 a.a. 1 - 630) Khu et al., 
2001
pFG114 pXJmyc-NS3 (myc-NS3 a.a. 1 – 630) Khu et al., 
2001
pFG134 pAS-C-Stu1 (NS3 a.a. 1 – 538) Khu et al., 
2001
pFG135 pAS-C-AflIII (NS3 a.a. 1 – 430) Khu et al., 
2001
pFG136 pAS-C-BstEII (NS3 a.a. 1 – 328) Khu et al., 
2001
pFG137 pAS-C-SspI (NS3 a.a. 1 – 335) Khu et al., 
2001
pFG138 pAS-C-SphI (NS3 a.a. 1 – 149) Khu et al., 
2001
pFG146 pAS-N-Sma1 (NS3 a.a. 162 – 630) Khu et al., 
2001
pFG147 pAS-N-NdeI (NS3 a.a. 247 – 630) Khu et al., 
2001
pFG148 pAS-N-Ssp1 (NS3 a.a. 336 – 630) Khu et al., 
2001
pFG156 pAS-N-Nco1 (NS3 a.a. 57 – 630) Khu et al., 
2001
pFG157 pAS-helicase (NS3 a.a. 181 – 630) Khu et al., 
2001
pFG158 pACT-helicase (NS3 a.a. 181 – 630) Khu et al., 
2001
pFG159 pAS-Sma1-Nde1 (NS3 a.a. 162 – 246) Khu et al., 
2001
pFG161 pAS-Nde1-Ssp1 (NS3 a.a. 247 – 335) Khu et al., 
2001
pFG150 pAS-min (SmaI-SspI, NS3 a.a. 162-335) Khu et al., 
2001
pFG171 pACT-min (SmaI-SacI, NS3 a.a. 181 – 375) Khu et al., 
2001
pFG188 pXJmyc-min (myc-NS3 a.a. 181- 375) Khu et al., 
2001
pFG162 pGEX-helicase (NS3 a.a. 181 – 630) Khu et al., 
2001
pFG166 pFG150 cut with EagI and BstEII and religated Khu et al., 
2001
26
Table 2-3.  Plasmids used in studying NS3 LMP7 interaction
Plasmid Description Source
pFG105 pAS-NS3 (NS3 a.a. 1 – 630) Khu et al., 
2001
pFG109 pXJflag-NS3 (flag-NS3 a.a. 1 - 630) Khu et al., 
2001
pFG346 pXJflag-GST (flag-GST) Glaxo lab, 
IMCB
pFG440 pXJflag-NS3-NdeI (flag-NS3 Nde I a.a. 1 - 310) This work
pFG443 pXJflag-NS3-protease (flag-NS3 protease a.a. 1 - 180) This work
pFG211 pXJflag-NS3-helicase (flag-NS3 helicase a.a. 181 – 630) Khu et al., 
2001
pXJmyc-C1-28 (myc-LMP7 a.a. -3 - 297) This work
pFG396 pXJmyc-LMP7 (myc-LMP7 a.a. 1 - 277) This work
pFG409 pXJmyc-C200LMP7 (myc-LMP7 a.a. 1 - 200) This work
pFG408 pXJmyc-C160LMP7 (myc-LMP7 a.a. 1 - 160) This work
pFG407 pXJmyc-C120LMP7 (myc-LMP7 a.a. 1 - 120) This work
pFG422 pXJmyc-N40LMP7 (myc-LMP7 a.a. 40 - 277) This work
pFG423 pXJmyc-N80LMP7 (myc-LMP7 a.a. 80 - 277) This work
pFG282 pGEX-NS3  (GST-NS3 a.a. 1 - 630) This work
pFG397 pGEX-LMP7 (GST-LMP7 a.a. 1 - 277) This work
pFG380 pGEX-NS5A5B  (GST-NS5A5B cleavage site 
EEASEDVVPCSMSYTWTGACCFGTM)




3.1 Characterization of NS3-NS3 interaction
3.1.1 Delineating the region of self-interaction in NS3
Protein-protein interactions among all HCV proteins were tested and NS3 was 
found to interact strongly with itself.  To delineate the region(s) of NS3 important for 
interaction with itself, N and C terminal deletion mutants of NS3 were generated, in 
frame with the DNA-binding domain pAS2-1.  These mutants were tested for 
interaction with full-length NS3 in the yeast-two hybrid assay (Figure 3-1).  The C-
terminal region from aa 336 to 630 containing the RNA-binding motif is apparently 
not required for NS3-NS3 interaction in this assay.  The minimal region for interaction 
is from aa 181 to 335, which includes motifs essential for NTP-binding, NTPase, and 
helicase activities.  Although the minimal region defined was sufficient for interaction, 
other parts of the NS3 protein may also contribute to the stability of NS3-NS3 
interaction.  Deletion of the protease domain and the C-terminal half of the NS3 
protein containing the RNA-binding motif reduces the strength of the interaction.  The 
NS3-NS3 interaction was also confirmed by co-expressing myc-tagged and flag-tagged 
NS3 in COS-7 cells and showing their association by co-immunoprecipitation 
experiments (Figure 3-2).  Since the protease region (aa 1 to 180) is not required for 
interaction, our studies on NS3-NS3 interaction will focus on the helicase region.
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Figure 3-2.  Immunoprecipitation between flag-tagged NS3 and myc-tagged NS3.
COS-7 cells were transfected with constructs expressing flag-NS3 and a construct expressing myc-NS3 or 
with myc-NS3 alone.  Total protein (150 µg) from transfected cells were used for immunoprecipitation using 
anti-flag agarose gel.  myc-NS3 was detected in the complex precipitated with an anti-flag gel, 
demonstrating interaction between myc-NS3 and flag-NS3 (lane 1).  myc-NS3 was not precipitated by the 
anti-flag gel in the absence of flag-NS3, showing the specificity of the anti-flag gel used for 
immunoprecipitation (lane 2).  1/10 of the input immunoprecipitated proteins were probed with anti-flag 
antibody to show that flag-NS3 was specifically precipitated by the anti-flag gel (lanes 3, 4).  Cell lysates 
(20 µg) were loaded to detect the expression of each of the tagged NS3 proteins in transfected cells (lanes 5, 
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The interactions between the N- and C- terminal regions of the helicase were also 
tested using yeast-two hybrid assay (Figure 3-3).  The minimal region was found to 
interact with itself and does not interact with the C-terminal portion containing the RNA-
binding region.  This interaction was also confirmed by co-immunoprecipitation in COS-7 
cells (Figure 3-4).  Under gel filtration conditions, however, the N-terminal minimal 
region did not bind to helicase or itself (data not shown), suggesting that these conditions 
were not conducive to such interactions and that additional factors in cells or the cellular 
environment may be required for the minimal region to bind to NS3 and to itself.
Figure 3-3. The NS3 helicase interacts in an N-to-N orientation.
The full-length and truncated helicases were tested for interaction with one another using the yeast two-
hybrid assay.  The minimal region interacted well with the helicase domain and with itself, but not with the 





























Figure 3-4. Minimal region found to interact with helicase domain and itself.  
COS-7 cells were transfected with the various constructs as indicated.  Cell lysate (150 µg) were 
immunoprecipitated with anti-flag agarose gel, and bound proteins were detected with anti-flag or anti-myc 
as indicated.  The minimal region (myc-min) immunoprecipitated with full-length NS3 (lane 1).  The 
minimal region associated with itself (lane 2).  Full-length myc-NS3 and myc-min were not precipitated by 
anti-flag beads, showing the specificity of the anti-flag beads (lanes 3, 4).  Western blots of the transfected 
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3.1.2 Expression and purification of recombinant NS3 helicase for gel 
filtration analysis
The helicase was bacterially expressed, purified (Figures 3-5, 3-6) and run through 
an analytical FPLC column in the presence and absence of an oligonucleotide.  This was 
done to determine if the helicase forms a dimer or higher oligomer, and if the 
oligomerization was dependent on the binding of an oligonucleotide.  The helicase was 
found to exist as a monomer in the absence of an oligonucleotide under the conditions 
used.  When an oligonucleotide was added, however, the protein shift to a dimer form and 
no higher oligomer was observed (Figure 3-7).  The proportion of dimer versus monomer 
increased as the molar ratio of oligonucleotide to protein increased.  The monomer and 
dimer peaks merge, indicating a dynamic equilibrium between the two forms.  Under these 
conditions, the presence of an oligonucleotide is required for dimerization, and NTP 
binding and hydrolysis are not necessary, since no NTP was added in these assays.  The 
oligonucleotide used in these experiments was 39-mer, which should be long enough to 
accommodate an active helicase complex, as previous studies showed that a 20-mer 3’ 
overhang is sufficient for the binding and subsequent unwinding of the double stranded 
duplex DNA (Tai et al., 1996).  The formation of oligomers using chemical cross-linkers, 
BS3 and glutaraldehyde were also tested.   In the presence of the cross-linkers, higher 
oligomers were observed even in the absence of an oligonucleotide, suggesting that cross-
linking reactions may be nonspecific (data not shown).
33
Figure 3-5. Recombinant NS3 helicase expression.
Bacteria induced to express GST-helicase were lysed.  Total protein (2 µg) before binding on GSH beads 
(lane 1), GST-helicase bound on GSH beads before thrombin cleavage (lane 2) and helicase protein with 
GST moiety cleaved by thrombin (lane 3), were separated on a 10% SDS-PAGE gel and stained with 



















Figure 3-6. Purification of NS3 helicase by FPLC.
The helicase protein was purified from contaminants by FPLC as shown by the absorbance graph.  After 






























































Figure 3-7. Gel filtration of wild-type helicase.
Proteins standards were run to calibrate the column, with each peak representing a protein of a particular 
molecular weight.  Their molecular weights are indicated on the peaks.  In the absence of an oligonucleotide, 
helicase elutes at around 60 kDa, indicating that it exists as a monomer in the absence of an oligonucleotide.  
As increasing amount of an 39-mer oligonucleotide (0, 0.5 and 5.0 µM) were added with a fixed amount of 






Since oligomerization has been proposed to enhance helicase activity (Levin and 
Patel, 1999), helicase mutants defective in self-interaction may be inactive for their 
unwinding activity because of their inability to from dimers or oligomers.  To investigate 
the possibility that mutations in conserved motifs for NTP-binding, NTPase, and helicase 
activities are inactive because of their failure to form oligomers, some of these sites are 
mutated using site-directed mutagenesis.  The sequences G207SGKST, D290ECH, and 
T322AT were mutated to AAGKST, DECA, and AAA, respectively, which have been 
shown to inactivate helicase activities (Heilek and Peterson, 1997; Kim et al., 1997).  
These helicase mutants were expressed in yeasts and in bacteria to test for interaction by 
the yeast two-hybrid method and gel filtration, respectively.  Mutants with changes in 
these three conserved motifs were able to interact with wild-type helicase in the yeast two-
hybrid test.  Gel filtration of these mutants also showed that they are able to form dimers 
in the presence of an oligonucleotide (Figure 3-8).  The loss of helicase activity of these 


































Figure 3-8. Gel filtration of helicase mutants.
Helicase mutants (5 µM) with mutations in the conserved motifs that abolished the helicase activity (DECH 
 DECA and TAT  AAA) purified by FPLC was analyzed and found to form dimers in the presence of 






3.1.3 Analytical gel filtration of dimerization mutants
Whether the HCV helicase functions as a monomer or a dimer has been in 
contention for a while.  The generation of mutants that disrupt the interaction between the 
helicase molecules would help to correlate the lack of interaction with the presence or 
absence of helicase activity of these mutants.  Random mutations that disrupt the 
interaction between the minimal interacting domains were generated by amplifying the 
minimal region under low-fidelity conditions and co-transformed with a gapped plasmid 
into PJ69-2A (see Material and Methods, Figure 2-1).  The two fragments were repaired in 
yeast cells, and colonies were selected and screened for mutants that showed no growth on 
–His plates.  About 500 clones were screened, and 13 His- mutants with mutations that 
disrupted interaction between a mutant and a wild-type minimal region were isolated.  The 
mutated regions from these mutants were sequenced, and the positions of the mutations 
found are shown in Figure 3-9.  The mutations appeared to cluster in a few pockets, 
around aa 200, 268, 290, and 311.  These may define the residues that form non-covalent 
bonds with another helicase.
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The mutations were transferred into a full-length helicase, and the mutants 
were again tested for their ability to interact with a wild-type helicase.  None of the 
dimerization mutants except S268P, of the full-length helicase showed a complete loss 
of interaction, as they were His+, in the yeast two-hybrid test.  The HIS3 gene, 
however, is a very sensitive reporter gene and allows cells to grow on –His medium 
even upon weak activation.   These mutants showed weaker interaction that the wild-
type helicase, which activates all three reporters (Figure 3-9).  Therefore, single 
mutations in the helicase context are not sufficient to abolish interaction completely.  
Additional points of contact outside the minimal region might compensate for the 
binding in vivo.  The S268P mutation abolished interaction completely, but the change 
generated a proline, which is generally disruptive to a protein structure and was not 
chosen for further analysis.  To confirm that the mutants show weak interaction with 
themselves, three mutants, T266A, Y267S, and M288T, were expressed in bacteria, 
purified and subjected to analytical gel filtration.  Using the LOOK programme, these 
mutations were chosen for biological studies because they were predicted to be within 
beta-sheets and are less likely to cause major disruption to the structure of the helicase.  



































Figure 3-10. Gel filtration of dimerization mutants.
Three dimerization mutants, T266A, Y267S, and M288T (see Figure 3-9), purified by FPLC, were 
analyzed for their ability to dimerize by gel filtration.  All three, each at 5 µM, showed a larger 
monomer peak and a reduced dimer peak in the presence of 5.0 µM 39-mer oligonucleotide.  The gel 






3.1.4 Correlation between dimer formation and helicase activity
The wild-type helicase and dimerization mutants (T266A, Y267S, and M288T) 
were assayed for their helicase activities in an in vitro assay (Tai et al., 1996) using 
double stranded DNA oligonucleotide as a substrate.  Wild-type helicase unwound the 
substrate within 30 s, while all the dimerization mutants unwound the substrate at a 
reduced rate (Figure 3-11).  The wild-type helicase released up to 50 % of single-
stranded oligonucleotide, while mutants T266A and Y267S were relatively inactive 
(Figure 3-12).  The M288T mutant showed a lower rate of unwinding but eventually 
unwound up to 45% of double stranded DNA (Figure 3-12).  As a negative control, the 
AAA mutant, which has no helicase activity, was also included.  We have identified 
mutations that abolished dimer formation and also affect the activities of the HCV 
helicase to various degrees, indicating that helicase activity is dependent on 
dimerization.
Figure 3-11. Helicase assays of wild-type helicase, mutants Y267 and AAA.
Autoradiography showing helicase activities of wild-type helicase, dimerization mutants Y267 and 
AAA.  Activity is depicted by the unwinding of radioactively labeled double stranded DNA to release 
single-stranded DNA.  Each reaction mix contained 200 nM helicase and 60 nM substrate.  The two 
control lanes on the extreme left showed the positions of single- and double stranded oligonucleotides 
(in the absence of helicase).  Protein bound DNA is also indicated.  
wildtype
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Figure 3-12. Dimerization mutants shows reduction  in helicase activity.
Radioactive signals from the helicase assays (Figure 3-11) performed on wild-type and mutant helicases 
(T266A, Y267S, M288T, and AAA) were quantitated on a phosphorimager and the percent DNA 































To confirm this finding, the helicase activity of wild-type helicase when the 
helicase mutants AAA and Y267S were added to the wild-type helicase in increasing 
amounts, was measured.  A previous study showed the addition of an inactive helicase 
mutant to wild-type helicase was able to inhibit the helicase activity, leading to the 
conclusion that the HCV helicase acts as a dimer or higher oligomer (Levin and Patel, 
1999).  We have shown that Y267S is defective both in dimerization and helicase 
activity.  Therefore Y267S is not expected to bind to wild-type helicase, and the 
helicase activity of wild-type helicase should not be affected when increasing amount 
of mutants are added, since inactive wild-type-mutant dimers would not be formed.  
Indeed, the addition of mutant Y267S to wild-type helicase does not affect the helicase 
activity significantly.  When the ratio of Y267S to wild-type helicase was raised to 1:1, 
the percent unwound DNA decreased by 10% compared to that obtained with the wild-
type helicase only (Figure 3-13).  As control, the same experiment was repeated with 
mutant AAA, which is able to dimerize but not able to unwind double-stranded 
substrate.  We found that AAA mutant or AAA-wild-type helicase mixture bound to 
the substrate and did not release the single-stranded oligonucleotide.  As expected, 
AAA dramatically reduced the helicase activity as the ratio of mutant to wild-type 
protein increased (Figure 3-13).  An equimolar ratio of mutant AAA and wild-type 
helicase reduced the percent unwound DNA by about 40% compared to that obtained 
with wild-type helicase alone.    
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Figure 3-13. Inhibition of helicase activities by the additions of mutant proteins.
Wild-type helicase (400 nM) was mixed with 0, 100, 200, and 400 nM concentrations of mutant helicase 
Y267S or AAA and 20 nM radioactively labeled double stranded DNA substrate.  The triangles on the 
right indicate the magnitude of decrease in percent unwinding as the concentration of each of the mutant 
proteins was increased.   
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3.2 Characterization of NS3-LMP7 interaction
3.2.1 Screening for NS3 host interacting partner
A spleen cDNA library was used instead of a liver library in yeast two-hybrid 
screens as a liver library repeatedly yielded many candidate genes encoding secreted 
proteins, and false positive candidates. The liver is known to express a large number of 
secreted proteins that are not likely to interact with NS3, a cytoplasmic protein.  
Besides the liver, HCV has been reported to infect B cells as well (Zignego et al., 
1992; Sung et al., 2003) and the spleen is the organ from which B cells originate. 
Yeast two-hybrid screens of a human spleen cDNA library with NS3 as bait 
identified a clone encoding LMP7, a beta subunit of the immunoproteasome complex. 
This clone (C1-28) included the full-length coding sequence and 9 nucleotides of the 
5’ UTR of the LMP7 gene.  The LMP7 gene in pACT from the spleen cDNA library 
was re-cloned into pXJ100-myc and the interaction between LMP7 and NS3 was 
checked by in vitro binding assay.  35S-methionine-labeled LMP7 was incubated with 
either GST-NS3 or GST bound to beads (Figure 3-14). LMP7 bound to GST-NS3 but 
not GST (Figure 3-15), confirming the interaction shown by yeast-two hybrid assays, 
and indicating that the interaction between LMP7 and NS3 is specific.
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Figure 3-14.  Recombinant GST-NS3 and GST expression.  
Recombinant GST and GST-NS3 were expressed in bacteria and bound to GSH beads.  Two µg protein 
was separated on an SDS-PAGE gel and stained with Coomassie Brilliant Blue.  Molecular weight 
markers are indicated on the left.
Figure 3-15. NS3-LMP7 interaction shown by in vitro binding assay.
LMP7 was 35S-met-labeled in in vitro transcription–translation reaction using pXJmyc-C1-28 as 
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3.2.2 Delineating the region of interaction between NS3 and LMP7.
To determine the region in NS3 that interacts with LMP7, several deletion 
mutants were generated.  Constructs expressing the flag-tagged full-length NS3 and 
deletion mutants (Figure 3-16A) and myc-tagged LMP7 (LMP7 coding region 
amplified by PCR from the spleen cDNA library) were co-transfected into COS-7.  
LMP7 was found to co-immunoprecipitate with full length NS3 and the N-terminal 
region containing the protease domain of NS3 (Figure 3-16B, lanes 2, 6, 8), but not 
with the helicase domain of NS3 (Figure 3-16B, lane 4).  As a negative control, myc-
GST was also co-transfected with the different flag-NS3 deletion constructs (Figure 3-
16B, lanes 1, 3, 5, 7).  LMP7 was found to bind specifically to the minimal region 
containing the protease domain of NS3 (a.a. 1-180) (Figure 3-16B).
Similarly, to determine the region on LMP7 that interacts with NS3, several 
deletion mutants of LMP7 were also generated (Figure 3-17A).  Myc-tagged LMP7 
and LMP7 deletion mutants were co-expressed with flag-tagged NS3 or GST. Deletion 
from the C-terminus of LMP7 did not affect its co-immunoprecipitation with NS3 
(Figure 3-17B) but deletion of the first 40 amino acids from the N terminus reduced 
the association of LMP7 with NS3 drastically (Figure 3-17C, lanes 9, 11). GST did not 
co-immunoprecipitate with any of the LMP7 deletion mutants. These results indicate 
that NS3 interacts with the N terminus of LMP7, and the strongest interacting domain 
was found to be between a.a. 1-40, which contains the LMP7 prosequence (Figure 3-
17C).
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Figure 3-16.  LMP7 interacts with the protease domain of NS3.
(A) A schematic representation of the deletion mutants of NS3 and their ability to co-immunoprecipitate 
with LMP7 is summarized. The minimal region that interacts with LMP7 is the protease domain of NS3 
(a.a. 1-180). (B) COS-7 cells were transfected with various constructs as indicated. 150 µg of total 
protein was incubated with anti-flag agarose gel, and bound proteins were detected with either anti-flag 
or anti-myc antibodies.  As a negative control, cells were co-transfected with constructs expressing myc-
GST and full-length flag-NS3 or flag-NS3 mutants. Myc-LMP7 co-immunoprecipitated with full-length 
flag-NS3 (lane 2), flag-NS3 NdeI (lane 6) and flag-protease (lane 8), but did not did not bind to flag-
helicase (lane 4).  Myc-GST did not co-immunoprecipitate with all the flag-tagged proteins (lanes 1, 3, 
5, 7).
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Figure 3-17.  NS3 interacts with the prosequence of LMP7.
(A) Deletion mutants of LMP7 are schematically depicted. Their ability to co-immunoprecipitate with 
NS3 are indicated, with (++) and (+/-) representing strong and weak binding respectively.  NS3 
interacted mainly with the N terminal region (a.a. 1-40) of LMP7. (B) COS-7 cells were transfected with 
constructs expressing myc-LMP7 and C-terminally deleted mutants, together with flag-NS3. 150 µg of 
cell lysate was immunoprecipitated with anti-flag agarose gel, and bound proteins were detected with 
either anti-flag or anti-myc antibodies. Full length myc-LMP7 (lane 1), myc-C200LMP7 (lane 3), 
myc-C160LMP7 (lane 5), myc-C120LMP7 (lane 7) co-immunoprecipitated with flag-NS3.  None of 
the LMP7 proteins interacted with flag-GST (lanes 2, 4, 6, 8). (C) Similarly, co-immunoprecipitation 
between full-length flag-NS3, and N terminus deletion LMP7 mutants was studied.  Full-length myc-
LMP7 (lane 13) co-immunoprecipitated with flag-NS3, but myc-N80LMP7 (lane 9) and myc-
N40LMP7 (lane 11) co-immunoprecipitated weakly with NS3. Flag-GST served as a negative control 
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3.2.3 Expression and purification of recombinant NS3 and LMP7 for in 
vitro assays
GST-NS3 was expressed in bacterial cells and purified by binding to GSH 
beads as described in Materials and Methods. The GST moiety could not be cleaved 
from NS3 with thrombin. The GST-NS3 fusion protein was eluted from beads using 
GSH.  The eluted protein was contaminated by smaller proteins of about 30 kDa 
(Figure 3-18A).  To further purify GST-NS3, fast performance liquid chromatography 
(FPLC) using a 1 ml HiTrap SP column (Pharmacia) was performed. The column was 
pre-equilibrated in buffer B and the proteins were eluted through a linear gradient of 0 
to 1 M NaCl in buffer B.  The contaminating proteins were found to elute in the earlier 
fractions (fractions 3 to 11) while the fusion protein concentrated in the later fractions 
(fractions 27 to 29) at about 400 mM NaCl (Figure 3-18B).  Fractions containing 
purified GST-NS3 were stored at – 80oC for future use.  All experiments were 
performed at 4oC unless otherwise stated. A GST-NS3 carrying a mutation in the 
protease domain, to be used as a control, was also expressed and purified in the same 
manner.  GST-LMP7 was similarly expressed in bacteria and purified on GSH beads. 
GST was cleaved from LMP7 by thrombin (Figure 3-19A).  An abundant 
contaminating protein at about 70 kDa was present in the supernatant and attempts 
were made to purify the protein by FPLC through a HiTrap SP column, through a 
NaCl gradient. LMP7 was found to elute in later fractions (fraction 38 onwards) at 
about 500 mM NaCl (Figure 3-19B).  These fractions were collected and checked for 
binding between purified recombinant LMP7 and NS3.  The purified preparations of 
NS3 (Figure 3-18B) and LMP7 (Figure 3-19B) used for protease assay were found to 
associate with each other.  LMP7 bound GST-NS3 but did not bind GST (Figure 3-
20A).
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Figure 3-18.  Purification of recombinant GST-NS3.
(A) Coomassie-stained SDS PAGE of GST-tagged full-length NS3.  Full-length GST-NS3 expressed in 
bacteria bound on glutathione (GSH) beads (lane 1).  GST-NS3 bound GSH beads after elution with 10 
mM GSH (lane 2).  Supernatants collected from four GSH washes of GST-NS3 bound beads (lane 3 to 
6). The washes were concentrated for purification by gel filtration.  (B) GST tagged NS3 purified by 
FPLC in HiTrap SP column.  Unbound contaminants eluted out in earlier fractions (fractions 3 to 11) 
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Figure 3-19.  Purification of recombinant LMP7.
(A) Coomassie-stained SDS PAGE showing full length GST-LMP7 expressed in bacteria bound on 
glutathione (GSH) beads (lane 1), GST-LMP7 bound GSH beads after cleavage with thrombin (1U/ml) 
(lane 2), supernatant collected from 2 sequential elution of LMP7 from beads (lanes 3, 4). The washes 
were concentrated for purification by gel filtration.  (B) LMP7 purified by FPLC in a HiTrap SP 
column.  Unbound contaminants eluted out in earlier fractions and LMP7 of relative purity were 























































3.2.4 Effect of LMP7 on NS3 protease activity
Since LMP7 interacted with the protease domain of NS3, the effect of LMP7 
on NS3 protease activity was investigated.  Protease activity was indicated by the 
cleavage of bead-bound 40 kD substrate, GST-NS5A5B, at the NS5A5B junction to 
produce a 30 kD cleavage product GST-NS5A, and a small NS5B peptide not visible 
on the gel.  GST-NS3-protease mutant (S138A) (Tomei et al., 1993) was similarly 
purified and assayed for protease activity.  No activity was detected, indicating that 
cleavage of GST-NS5A5B substrate was solely due to wild type (WT) NS3 and not to 
a contaminating bacterial protease (Figure 3-20B).  The protease assay was optimized 
and a 30 min incubation was found to be sufficient to detect protease activity (Figure 
3-20C).  With increasing amounts of LMP7 added to the protease assay, no notable 
change in NS3 protease activity was observed (Figure 3-20D), indicating that under 
these conditions, LMP7 does not have any effect on NS3 protease activity.  
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Figure 3-20.  In vitro binding of purified LMP7 to GST NS3 and protease activity 
of purified NS3.
(A) In vitro binding of LMP7 to GST-NS3.  200 ng LMP7 were incubated overnight with either 200 ng 
GST or GST-NS3 bound on GSH beads in lysis buffer at 4 ˚C.  The bound LMP7 was detected on 
western blots with anti-LMP7 antibody.  (B) Coomassie-stained SDS PAGE showing the cleavage of the 
NS3 substrate, GST-NS5A5B.  GST-NS5A5B expressed in bacteria bound on glutathione beads (lane 
1).  GST-NS5A5B substrate was cleaved by wildtype (WT) NS3 to release a smaller protein of 
approximately 30 kDa (lane 2). This showed that the purified GST-NS3 was active for protease activity.  
GST-NS3 protease mutant was unable to cleave substrate, showing that the GST-NS5A5B substrate was 
specifically cleaved by GST-NS3, and not by a co-purified contaminating bacterial protein (lane 3).  (C) 
Optimization of protease activity.  GST-NS3 protease activity was monitored over 60 min and the 
amount of cleaved products at different time intervals visualized on a Coomassie-stained SDS-PAGE 
gel.  Thirty min incubation was sufficient to detect protease activity.   (D) Different amounts of LMP7 
were added to GST-NS3.  Purified LMP7 did not cleave the GST-NS5A5B substrate (2 µg) , indicating 
that cleavage of GST-NS5A5B substrate was specifically due to GST-NS3 (lane 1).  GST-NS3 0.2 µg 
(0.1 µ) incubated with increasing amounts of purified LMP7, 0.2 µg to 0.6 µg (0.3 µ to 1.0 µ), 
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3.2.5 Effect of NS3 on proteasome activity
LMP7 is a beta subunit of the 20S proteasome, which is induced in the 
presence of IFN- (Figure 3-21A).  The 20S proteasome is associated with several 
peptidase activities, namely, chymotrypsin-like, trypsin-like, and post-acidic activities 
which can be assayed by the use of fluorogenic substrates LLVY-AMC, LRR-AMC 
and LLE-AMC respectively.  Firstly, co-immunoprecipitation of NS3 with proteasome 
complex was checked by adding IFN- to either NS3-transfected HeLa cells or GST-
transfected HeLa cells as control.  Proteasome complex was immunoprecipitated using 
agarose beads with antibodies to the alpha 4 subunit of the proteasome conjugated to 
them.  As control, rabbit anti-myc antibody and protein A beads were used.  The 
proteasome preparation was checked for the presence of LMP7 as well as the binding 
of NS3 on proteasome through LMP7.  LMP7 precipitated specifically with the anti-
alpha 4 beads but not with the protein A beads.  NS3 but not GST was found to co-
immunoprecipitate with the precipitated proteasome complex (Figure 3-21B).
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Figure 3-21.  NS3 binds to the immunoproteasome complex.
(A) HeLa cells were induced with IFN- in HeLa cells (lane 1), uninduced (lane 2), or transfected with a 
construct expressing myc-LMP7 as a control (lane 3).  Western blots of these cell lysates were probed 
with an anti-LMP7 antibody.  HeLa cells were transfected with constructs expressing flag-NS3 (B), or 
flag-GST (C) as control. Six hours after transfection, the cells were induced with IFN- for 24 h.  The 
cells were harvested and the proteasome complex immunoprecipitated from cell lysates with anti-alpha 
4 agarose beads or with anti-myc-protein A beads. LMP7 induced in the presence of IFN- (lanes 1 and 
7) and LMP7 present in the immunoprecipitated proteasome complex (lanes 2 and 8) were detected with 
anti-LMP antibodies. LMP7 was not precipitated with anti-myc antibody bound to protein A beads 
(lanes 3 and 9), indicating that LMP7 bound specifically to the proteasome complex. Exogenous flag-
NS3 (lane 4) and flag-GST (lane 10) in cell lysates, and flag-NS3 immunoprecipitated with proteasome 
complex (lane 5) were detected with anti-flag antibodies. Flag-GST did not co-immunoprecipitate with 
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Proteasome assays were optimized for immunoprecipitated proteasomes from 
IFN- induced HeLa and Huh-7 cells using three different fluorogenic substrates: 
LLVY-AMC for chymotrypsin-like activity, LRR-AMC for trypsin-like activity and 
LLE-AMC for post acidic activity.  For HeLa cells, 100 µM substrate and 0.6 µg 
immunoprecipitated proteins were found to be sufficient for detecting all three 
peptidase activities (Figures 3-22, 3-24, 3-26).  Similarly for Huh-7 cells, 100 µM 
substrate and 0.6 µg immunoprecipitated proteins were also found to be sufficient for 
detecting all three peptidase activities (Figures 3-28, 3-30, 3-32).  
Using the above predetermined amounts of substrate and immunoprecipitated 
proteins, the effect of NS3 on proteasome activity was examined in both flag-NS3 
transfected HeLa and Huh-7 cells.  Flag-GST was transfected as a control.  For HeLa
cells, no significant changes were observed for both chymotrypsin-like (Figure 3-23) 
and post acidic peptidase activities (Figure 3-27).  There was, however a general 
reduction in trypsin-like peptidase activity through the time course (Figure 3-25).  For 
Huh-7 cells, no significant changes were observed for all three peptidase activities 
(Figures 3-29, 3-31, 3-33).  The expression level of NS3 in Huh-7 cells is lower than in 
HeLa cells which could explain why no reduction in trypsin-like peptidase activity was 
observed (data not shown).
The presence of NS3 alone did not seem to be sufficient to exert any effect on 
proteasome activities, so proteasome were immunoprecipitated instead from 9-13 cell 
line carrying a HCV NS3-5B replicon, which expresses the other HCV viral proteins.  
Such replicon cell lines are widely used as models for studying HCV replication, as 
they represent a system where the HCV subgenomic RNA is supported by the HCV 
replicase, which comprises the HCV non-structural proteins.  They also represent a 
replication system close to a HCV in vivo replication condition.  Untransfected Huh-7 
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cells (parental cell line of 9-13) were used as control.  Both NS3 and LMP7 were 
detected in 9-13 cells but NS3 was not detected in the immunoprecipitated 
proteasomes complex (data not shown).  This could be due to the lower expression 
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Figure 3-22.  Chymotrypsin-like activity optimization in HeLa cells using 
substrate LLVY-AMC.
A range of amounts of protein (0.0, 0.3, 0.6, 1.2, 2.5 µg) containing immunoproteasome precipitated 
from IFN- induced HeLa cells were assayed for chymotrypsin-like activity with either 100 µM or 200 
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Figure 3-23. NS3 did not affect immunoproteasome chymotrypsin-like activity in 
HeLa cells.
Proteins (0.6 µg) containing immunoproteasome precipitated from IFN- induced HeLa cells transfected 
with either flag-NS3 or flag-GST as control, was incubated with 100 µM LLVY-AMC substrate over 50 
min with samples taken at every 10 min intervals. Peptidase activity was expressed as relative 
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Figure 3-24.  Trypsin-like activity optimization in HeLa cells using substrate 
LRR-AMC.
A range of amounts of protein (0.0, 0.3, 0.6, 1.2, 2.5 µg) containing immunoproteasome precipitated 
from IFN- induced HeLa cells were assayed for trypsin-like activity with either 100 µM or 200 µM 
LRR-AMC substrate.  Peptidase activity was expressed as relative fluorescence unit (RFU). 
Figure 3-25. NS3 reduces immunoproteasome trypsin-like activity in HeLa cells.
Proteins (0.6 µg) containing immunoproteasome precipitated from IFN- induced HeLa cells transfected 
with either flag-NS3 or flag-GST as control, was incubated with 100 µM LRR-AMC substrate over 50 
min with samples taken at every 10 min intervals. Peptidase activity was expressed as relative 
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Figure 3-26.  Post acidic activity optimization in HeLa cells using substrate LLE-
AMC.
A range of amounts of protein (0.0, 0.3, 0.6, 1.2, 2.5 µg) containing immunoproteasome precipitated 
from IFN- induced HeLa cells were assayed for post acidic activity with either 100 µM or 200 µM 
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Figure 3-27. NS3 did not affect immunoproteasome post acidic activity in HeLa
cells.
Proteins (0.6 µg) containing immunoproteasome precipitated from IFN- induced HeLa cells transfected 
with either flag-NS3 or flag-GST as control, was incubated with 100 µM LLE-AMC substrate over 50 
min with samples taken at every 10 min intervals. Peptidase activity was expressed as relative 
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Figure 3-28.  Chymotrypsin-like activity optimization in Huh-7 cells using 
substrate LLVY-AMC.
A range of amounts of protein (0.0, 0.3, 0.6, 1.2, 2.5 µg) containing immunoproteasome precipitated 
from IFN- induced Huh-7 cells were assayed for chymotrypsin-like activity with either 100 µM or 200 
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Figure 3-29. NS3 did not affect immunoproteasome chymotrypsin-like activity in 
Huh-7 cells.
Proteins (0.6 µg) containing immunoproteasome precipitated from IFN- induced Huh-7 cells 
transfected with either flag-NS3 or flag-GST as control, was incubated with 100 µM LLVY-AMC 
substrate over 50 min with samples taken at every 10 min intervals. Peptidase activity was expressed as 
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Figure 3-30.  Trypsin-like activity optimization in Huh-7 cells using substrate 
LRR-AMC.
A range of amounts of protein (0.0, 0.3, 0.6, 1.2, 2.5 µg) containing immunoproteasome precipitated 
from IFN- induced Huh-7 cells were assayed for trypsin-like activity with either 100 µM or 200 µM 
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Figure 3-31. NS3 did not affect immunoproteasome trypsin-like activity in Huh-7 
cells.
Proteins (0.6 µg) containing immunoproteasome precipitated from IFN- induced Huh-7 cells 
transfected with either flag-NS3 or flag-GST as control, was incubated with 100 µM LRR-AMC 
substrate over 50 min with samples taken at every 10 min intervals. Peptidase activity was expressed as 
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Figure 3-32.  Post acidic activity optimization in Huh-7 cells using substrate LLE-
AMC.
A range of amounts of protein (0.0, 0.3, 0.6, 1.2, 2.5 µg) containing immunoproteasome precipitated 
from IFN- induced Huh-7 cells were assayed for post acidic activity with either 100 µM or 200 µM 
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Figure 3-33. NS3 did not affect immunoproteasome post acidic activity in Huh-7 
cells.
Proteins (0.6 µg) containing immunoproteasome precipitated from IFN- induced Huh-7 cells 
transfected with either flag-NS3 or flag-GST as control, was incubated with 100 µM LLE-AMC 
substrate over 50 min with samples taken at every 10 min intervals. Peptidase activity was expressed as 










Three peptidase activities of the proteasome samples precipitated from both 
IFN- induced or un-induced 9-13 cells were tested under optimized conditions (100 
µM substrate, 0.6 µg proteasome).  The samples were, however, incubated for only 20 
min as this timing was determined by the earlier experiments to be within the range 
that is sensitive for detecting any change in peptidase activities.  The assays were also 
performed in the presence or absence of 10 µM clasto-lactacystin -lactone, which is a 
specific inhibitor of the proteasome.  -lactone inhibits proteasome activities by 
covalently modifying the threonine residues of the catalytic beta subunits (Craiu et al., 
1997).  Fluorescence obtained from untransfected Huh-7 cells was normalized as 
100%.  All three peptidase activities of the proteasome dropped significantly upon the 
addition of -lactone (Figures 3-34A, B, C), which verified that the peptidase activities 
observed were truly due to proteasome and not any other contaminating cellular 
peptidases.  In the absence of IFN-, there was minimal reduction in proteasome 
activities, however, after IFN- induction, chymotrypsin-like activity and trypsin-like 
activities were reduced to about 55% (Figures 3-34A, B), and post acidic activity was 
reduced most, to about 40% (Figure 3-34C).  These results suggest that the presence of 
the HCV proteins specifically inhibit the immunoproteasomes and not the constitutive 
proteasomes as reduction in peptidase activities were only observed with the addition 
of IFN-.    
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Figure 3-34.  Expression of NS3-NS5B viral proteins reduces the LMP7-
immunopropteasome activity.
Proteasome and immunoproteasome complexes precipitated from either 9-13 or Huh-7 cells were 
assayed for three different peptidase activities with or without 10 µM clasto-lactacystin -lactone (-
lactone).  Fluorogenic substrate (A) LLVY was used to test for chymotrypsin-like activity, (B) LRR for 
trypsin-like activity and (C) LLE for post-acidic activity.  For each substrate, the fluorescence signals 
obtained from proteasomes or immunoproteasomes precipitated from Huh-7 cells in the absence of -
lactone treatment, were standardized as 100% activity.  All other activities were expressed as a 
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4.1 NS3 NS3 interaction
The first part of this thesis describes the characterization of NS3 
homodimerization using a combination of yeast molecular genetic and biochemical 
techniques.  NS3 was found to dimerize through the N-terminal region of the helicase 
domain (Figure 3-3), and several random mutations generated were able to disrupt the 
interaction between two helicase molecules (Figure 3-10).  This lower affinity 
correlates with a loss of helicase activity (Figure 3-12), indicating the importance of 
dimerization for helicase activity.  Whether NS3 helicase exists and functions as a 
dimer has been a subject of debate.  Structural (Yao et al., 1997), mutational (Lin and 
Kim 1999), and equilibrium and velocity sedimentation centrifugation (Porter et al., 
1998) experiments suggested HCV helicase to function as a monomer, while others 
reported that it functions as an oligomer (Cho et al., 1998).  DNA helicases in 
Escherichia coli have been reported to function as monomers (Mechanic et al., 1999) 
or as oligomers (Bujalowski et al., 1994).  
In this study, NS3 helicase was shown to interact strongly with itself both in 
yeast two-hybrid assay and in co-immunoprecipitation experiments.  Gel filtration 
experiments also demonstrated that the helicase exists as a dimer in solution, and only 
in the presence of a single-stranded oligonucleotide.  The dependence of dimerization 
on the binding of a single-stranded DNA is reminiscent of the Escherichia coli Rep 
helicase (Wong et al., 1992).  Others have shown that the HCV helicase forms 
oligomers up to octamers in cross-linking studies (Levin and Patel 1999).  Under gel 
filtration conditions, we were able to detect only dimers and no higher oligomers.  The 
conditions used in our experiments may not allow for stable formation of higher 
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oligomers, although the buffer used for gel filtration is similar to those used in cross-
linking experiments in which HCV helicase was shown to form oligomers.
A dimer model for the NS3 helicase has been proposed based on the crystal 
structure of the NS3 helicase of HCV genotype 1b (Cho et al., 1998).  The authors 
suggested a head-to-tail, where the NTPase domain appears to contact the RNA-
binding domain.  Although our results showed that the interaction between helicase 
molecules occurs through the N terminus of the helicase domain in a yeast two-hybrid 
test as well as in co-immunoprecipitation experiments, the orientation of their 
interaction cannot be determined.  This minimal region is also unable to bind to itself 
under gel filtration conditions, indicating that these conditions may not mimic 
physiological conditions and/or that additional factors are needed to stimulate the 
dimerization of the minimal region.  From the gel filtration assays, the binding of a 
single-stranded oligonucleotide plays an important part in inducing dimer formation.
Since the helicase shows strong self-association, one wondered if it is 
important for optimal helicase activity.  The minimal region cannot bind to the helicase 
under gel filtration conditions, presumably because mutual binding of a single-stranded
DNA or RNA is necessary for stable dimer formation.  Therefore, we were unable to 
use the minimal region to inhibit dimerization of the full length helicase to assay its 
effect on the helicase activity in an in vitro assay.  
To test the hypothesis that dimerization is important for helicase activity, 
mutants that disrupted the interaction were isolated and assayed for helicase activities.  
One caveat in testing this hypothesis exists: these mutations may disrupt the structure 
of the helicase, so that both dimerization and helicase activity are affected.  Therefore, 
mutants (T266A, Y267S, and M288T) that are less likely to perturb the structure of the 
helicase were chosen to assay dimerization and helicase activities.  The reduction in 
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helicase activity of the three mutants is not due to their inability to bind the substrate, 
since all three mutants shifted the substrate to a higher-molecular weight form (Figure 
3-11 and our unpublished data).  The reduction in helicase activities as compared to 
that of the wild type could therefore be attributed to a reduction in dimer formation, 
suggesting that dimerization contributes to a more efficient unwinding activity of the 
NS3 helicase.  This deduction was also confirmed by the reduction in the activity of 
wild-type helicase on the addition of mutant AAA and by a less significant drop on the 
addition of a dimerization mutant, Y267S (Figure 3-13).
The requirement of dimerization of the NS3 protein for optimal helicase 
activity has interesting implications for HCV replication in infected cells.  Translation 
of the positive-strand RNA genome and processing of the polypeptide produces a 
single molecule of NS3.  If helicase activity is absolutely dependent on the 
dimerization of NS3, then multiple rounds of translation must be completed before 
active NS3 dimers are formed to facilitate RNA replication.  The requirement for 
dimerization may limit the rate of RNA replication and provide an explanation to the 
low rate of replication in the early phase of infection.  However, we believe that 
monomeric NS3 also possesses some helicase activity as two of the dimerization 
mutants (T266A and M288T) tested showed little dimerization but are able to unwind 
duplex DNA to some extend (Figures 3-10 and 3-12). 
The effect of mutations that disrupt dimerization on the replication of the HCV 
awaits testing in a cell culture system that expresses the viral genome containing these 
mutations.  The definition of critical residues involved in protein-protein contact could 
potentially provide useful information for designing compounds that specifically 
inhibit the dimerization.  Such inhibitors will be specific to this helicase, as the dimer 
structure of the HCV helicase is unique.                
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4.2 NS3 LMP7 interaction
The second part of this thesis focused on the search for a host protein that 
interacts with the HCV NS3 protein by yeast two-hybrid screen, and lead to the 
identification of LMP7, an interferon gamma (IFN-) inducible beta subunit of the 
proteasome. The core of the proteasome is a 20S barrel-like multicatalytic 
endopeptidase complex with a stack of four rings consisting of two outer identical 
alpha-rings and two identical inner beta-rings.  The alpha and beta rings are each made 
up of seven structurally similar alpha and beta subunits.  Eukaryotic core particles 
consist of six active sites, three on each of its two central beta-rings.  Two sites on 
subunits X (5), two sites on subunits Z (2) and the remaining two sites on subunits 
Y (1).  These catalytic sites are associated with several peptidase activities of the 20S 
core, including chymotrypsin-like activity, which cleaves after hydrophobic residues, 
trypsin-like activity, which cleaves after basic residues, and post-acidic activity, which 
cleaves after acidic residues (Orlowski 1990; Dick et al., 1998; Nussbaum et al., 
1998).  Upon viral infection or IFN- stimulation, beta subunits Y, X, and Z are down-
regulated and are replaced by LMP2 (1i), LMP7 (5i) and MECL-1 (2i) 
respectively, generating immunoproteasomes, which are responsible for the generation 
of MHC class I ligands for antigen presentation through the MHC class I pathway 
(Belich et al., 1994; Groettrup 1996).
The effect of LMP7 on NS3 protease activity and the effect of NS3 on 
immunoproteasomes were tested.  Since LMP7 interacts with the protease region of 
NS3, in vitro NS3 protease activity was assayed in the presence and absence of LMP7. 
Under our assay conditions, there was no change in the protease activity in the 
presence of LMP7 (Figure 3-20D).  The binding of LMP7 on NS3 protease domain 
neither enhanced nor reduced NS3 protease activity.  Their interaction probably did not 
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interfere with NS3 catalytic sites or cause any conformational change to NS3, as 
purified NS3 was found to be active. On the other hand, the recombinant LMP7 
expressed might not be folded into its native conformation after purification even 
though the purified form could still bind NS3 (Figure 3-20A).  The peptidase activity 
of LMP7 could not be tested as this subunit is only functional in the presence of other 
proteasome proteins of the 20S catalytic core. 
HCV NS3 shows the strongest interaction with the prosequence of LMP7 and 
binds very weakly (if at all) to LMP7 with the prosequence deleted (Figure 3-17C).  
When tested in NS3 transfected HeLa and Huh-7 cells, no significant changes in 
proteasome activities were detected.  The presence of the other viral proteins might be 
important in facilitating the interaction between NS3 and LMP7.  Since the replicase 
exists as a complex during HCV infection and NS3 is a key component of the HCV 
replicase complex, it is important to determine if proteasome activities are affected in 
the presence of all the components of the HCV replicase complex.  The 9-13 stable cell 
line, which expresses viral nonstructural proteins NS3 to NS5B, and the parental cell 
line, Huh-7 as a control, was used for this experiment. When the peptidase activities of 
the constitutive proteasome (i.e. without IFN-) were also tested, no changes were 
observed (Figure 3-22). Upon IFN- induction, all 3 peptidase activities were down 
regulated by about 50% in the presence of the HCV proteins (Figure 3-22), indicating
that only immunoproteasome activity, but not the constitutive proteasome activity, is 
affected when the HCV nonstructural proteins are expressed.
The mechanism of immunoproteasome inhibition by the binding of NS3 to 
LMP7 is unclear, however, these possibilities can be speculated: Firstly, the processing 
of the LMP7 prosequence may be affected.  Immature LMP7 (i.e. LMP7 with 
prosequence) was not detected when NS3 was over expressed (Figure 3-21B), 
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indicating that the binding of NS3 to the prosequence does not affect the cleavage of 
the prosequence of LMP7.  Secondly, NS3 may sequester LMP7, thus lowering the 
pool available for assembling into immunoproteasomes. This is not likely the case, as 
the LMP7 detected upon IFN- induction and the amount of LMP7 detected in the 
precipitated proteasomes did not seem to change in the presence or absence of NS3 or 
NS3-5B (data not shown). 
Thirdly, the possibility that the assembly of proteasome complexes is affected 
in the presence of NS3 is also conceivable.  During proteasome assembly, the different 
alpha and beta subunits come together to form half-proteasomes, each half consisting 
of a full alpha ring and a ring of unprocessed beta subunits. The half-proteasomes 
dimerize and the prosequences are autocatalytically removed from the beta subunits, 
exposing the N-terminal catalytic threonine and rendering the 20S proteasome 
proteolytically active (Chen and Hochstrasser 1996; Schmidtke et al., 1997).  
Prosequences, exclusive to the proteasome  subunits, are important for the assembly 
of proteasome subunits to generate catalytically active proteasome (Lowe et al., 1995), 
as deletion of the propeptides results in reduced proteasome activities, defects in 
proteasome assembly and premature inactivation of the N-terminal active site (Arendt 
et al., 1999; Jager et al., 1999).  Therefore the binding of NS3 to LMP7 prosequence 
could impede the efficient dimerization and processing of the half-proteasomes during 
assembly, thereby causing reductions in immunoproteasome peptidase activities. 
Further biochemical characterization is necessary to determine if partially assembled 
immunoproteasomes accumulates when NS3 is over expressed.
Fourthly, the composition of immunoproteasomes may be altered, thereby 
shifting the peptidase activities detected. Immunoproteasomes with these 3 
combinations have been reported: those consisting of either LMP7 alone, LMP2 and 
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MECL-1, and all three inducible subunits (Groettrup et al., 2001). The modified 
proteolytic specificities of these immunoproteasomes generate a different spectrum of 
peptides from that of constitutive proteasomes. Immunoproteasomes were generally 
reported to have enhanced cleavage after hydrophobic and basic residues but a reduced 
cleavage after acidic residues (Driscoll et al., 1993; Gaczynska et al., 1993; Gaczynska 
et al., 1994).  
LMP7 is one of the IFN- inducible catalytic subunits of the 20S proteasome.  
Proteasomes are multisubunit, multicatalytic proteases that represent a major non-
lysosomal proteolytic machinery of eukaryotic cells (Coux et al., 1996).  Although 
they are found in all eukaryotic cells, the concentration of proteasomes varies 
substantially among different cell types.  The liver, spleen and lung constitute the 
highest level of proteasomes and levels are significantly lower in the skeletal muscle, 
brain and kidney (Tanaka et al., 1986).  Proteasomes are also particularly abundant in 
cancerous cell lines, such as human and rat hepatomas (Ichihara et al., 1993).  They are 
implicated in cellular processes which include the degradation of short-lived regulatory 
proteins, such as cyclins and transcription regulators, and the removal of misfolded 
proteins, and are also shown to be involved in apoptosis (Hilt and Wolf 1996) and to 
play a central role in the production of peptides for presentation by MHC class I 
molecules (Rock et al., 1994).  Inhibitors of the proteasomes were found to block the 
degradation of most cellular proteins as well as the generation of the majority of class-I 
presented peptides (Craiu et al., 1997).  Constitutive proteasomes are reported to be 
replaced by immunoproteasomes during viral or bacterial infection, and cytotoxic T 
lymphocytes response is directed mainly to immunoproteasome-generated T cell 
epitopes (Khan et al., 2001).  It is conceivable that HCV suppresses the activity of 
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immunoproteasomes, leading to pathogenesis and allowing the virus to escape the T-
cell mediated immune surveillance mechanism.
Viral evasion of the immune system through the interference of proteasome 
activity was proposed for several viruses.  The hepatitis B virus X protein was reported 
to interact with the alpha 4 subunit of the proteasome, causing reductions in 
proteasome activities (Hu et al., 1999).  LMP7 expression is necessary for the 
processing of an antigen of HBV core protein (Sijts et al., 2000) and epitope 
presentation of the HIV-1 reverse transcriptase (Sewell et al., 1999).  The human T cell 
leukemia virus type 1 Tax protein, however, binds to two proteasome subunits, alpha 3 
and beta 7, and stimulated proteasome activities (Hemelaar et al., 2001).
During the acute phase of infection, the presence of inflammatory cytokines 
drives the synthesis of LMP2, LMP7 and MECL-1.  As the infection progresses, 
cytokine levels decrease, which eventually leads to chronic diseases.  In the case of 
HCV infection, the persistence of the virus could well be exacerbated by the 
interaction of NS3 with immunoproteasome, thereby reducing the immunoproteasome 
activities. 
The development of anti HCV drugs has predominantly focused on the antiviral 
effect of interferon alpha and beta.  Although the use of interferon alpha alone or in 
combination with ribavirin, a nucleoside analogue, on patients with chronic hepatitis C 
have yielded encouraging results, these therapies are often accompanied by undesirable 
side effects (Neumann et al., 1998; Di Bisceglie and Hoofnagle 2002).  The 
mechanism by which NS3 alters immunoproteasome activity is still not known and 
much work is needed to understand the biological consequence of this inhibition. Our 
findings suggest that IFN- induced immunoproteasome activity is inhibited in the 
presence of nonstructural proteins NS3-5B, possibly through the interaction of NS3 
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with LMP7, and consequently, the presentation of viral antigens may be affected.  This 
could eventually contribute to the persistence of HCV in infected patients. The 
possibility of an alternative mechanism by which HCV could deploy to evade and 




The successful invasion and propagation of a virus in a host cell requires 
interactions between both viral-viral components as well as viral-host protein 
interactions.  Findings in this thesis, includes the identification of HCV NS3 
dimerization, important for optimal helicase activity, as well as the association 
between NS3 and LMP7, which reduces immunoproteasome activity.  Taken together, 
these information may aid in the understanding of HCV replication and the pathogenic 
effect of this virus.  We are slowly piecing the puzzles together and it is no doubt a 
long and tedious process worth investing time and effort in, as every small piece of 
puzzle solved contributes towards the development of more efficient therapies for 
HCV infected patients.  
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